These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8511115)

  • 1. [Biological markers of cancer. Critical study].
    Bellet D; Bidart JM
    Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
    Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
    J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the role of established tumour markers.
    Beastall GH; Cook B; Rustin GJ; Jennings J
    Ann Clin Biochem; 1991 Jan; 28 ( Pt 1)():5-18. PubMed ID: 2024935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
    Canil CM; Tannock IF
    Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in biological markers for cancer.
    Klavins JV
    Ann Clin Lab Sci; 1983; 13(4):275-80. PubMed ID: 6194735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical relevance of tumor markers].
    Lamerz R
    Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms.
    Marcillac I; Troalen F; Bidart JM; Ghillani P; Ribrag V; Escudier B; Malassagne B; Droz JP; Lhommé C; Rougier P
    Cancer Res; 1992 Jul; 52(14):3901-7. PubMed ID: 1377600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Biomarkers in Screening for Cancer.
    Duffy MJ
    Adv Exp Med Biol; 2015; 867():27-39. PubMed ID: 26530358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: Results from a 12-year experience.
    Wen YH; Chang PY; Hsu CM; Wang HY; Chiu CT; Lu JJ
    Clin Chim Acta; 2015 Oct; 450():273-6. PubMed ID: 26344337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects.
    Sisinni L; Landriscina M
    Adv Exp Med Biol; 2015; 867():159-76. PubMed ID: 26530366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor markers of breast cancer].
    Sławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytochemical evaluation of human esophageal neoplasms and preneoplastic lesions for beta-chorionic gonadotropin, placental lactogen, alpha-fetoprotein, carcinoembryonic antigen, and nonspecific cross-reacting antigen.
    Burg-Kurland CL; Purnell DM; Combs JW; Hillman EA; Harris CC; Trump BF
    Cancer Res; 1986 Jun; 46(6):2936-43. PubMed ID: 2421889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer.
    Louhimo J; Kokkola A; Alfthan H; Stenman UH; Haglund C
    Int J Cancer; 2004 Oct; 111(6):929-33. PubMed ID: 15300805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
    Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
    Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical application of tumour markers: a review.
    Amayo AA; Kuria JG
    East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The "false positive" tumor marker in malignant testicular tumor].
    Bussar-Maatz R; Weissbach L; Dahlmann N; Mann K
    Urologe A; 1993 May; 32(3):177-82. PubMed ID: 8511831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of tumour markers, cytogenetics.
    Lamerz R
    Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.